Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects

NCT02546323 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02546323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02546323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
September 17, 2015
Completion date
January 29, 2019
Enrollment
543 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis